Affy Marks End of 'Days of Fixed Content Arrays,' Reaffirms Sequencing Not a 'Strategic Fit'

According to CEO Kevin King, Affy may revisit the idea of becoming a player in the next-gen sequencing market "perhaps in the future," but its current focus is on "leading in exploration and growing our business in validation and routine testing."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.